Life Bio reaches first clinical milestone for OSK therapy
First patient dosed in Phase 1 trial testing epigenetic restoration approach for progressive age-related vision loss. The longevity…
FDA clears first human trial of epigenetic reprogramming therapy
A milestone moment for longevity as Life Biosciences gets green light to progress cellular rejuvenation trial in eye…
NewLimit ‘close’ to clinic-ready epigenetic reprogramming therapy
Liver rejuvenation program produces a ‘lead payload’ as biotech begins its journey towards human clinical trials. After several…
Lilly invests in epigenetic reprogramming biotech
NewLimit adds $45m in new funding at a $1.6bn valuation following preclinical progress that brings clinical trials closer…